{"id":65682,"date":"2026-05-19T21:57:09","date_gmt":"2026-05-19T13:57:09","guid":{"rendered":"https:\/\/flcube.com\/?p=65682"},"modified":"2026-05-19T21:57:10","modified_gmt":"2026-05-19T13:57:10","slug":"hengruis-her3-targeting-adc-shr-a2009-achieves-phase-iii-success-in-egfr-mutated-nsclc-after-tki-failure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65682","title":{"rendered":"Hengrui&#8217;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that the <strong>Phase III SHR-A2009-301 trial<\/strong> for its investigational <strong>HER3-targeting antibody drug conjugate (ADC) SHR-A2009<\/strong> met its <strong>primary endpoint with statistical significance<\/strong> in patients with <strong>advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> harboring <strong>EGFR mutations<\/strong> who have <strong>failed prior EGFR tyrosine kinase inhibitor (TKI) therapy<\/strong>. The study demonstrated that SHR-A2009 <strong>significantly prolonged progression-free survival (PFS)<\/strong> compared to <strong>platinum-based doublet chemotherapy<\/strong>, establishing a potential new standard of care in this difficult-to-treat population.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-amp-design\">Clinical Trial Results &amp; Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Name<\/strong><\/td><td>SHR-A2009-301<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>EGFR-mutated advanced\/metastatic NSCLC patients who failed prior EGFR TKI therapy<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Platinum-based doublet chemotherapy<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-Free Survival (PFS)<\/td><\/tr><tr><td><strong>Key Finding<\/strong><\/td><td>Statistically significant PFS improvement with SHR-A2009<\/td><\/tr><tr><td><strong>Therapeutic Setting<\/strong><\/td><td>Post-TKI failure, representing high unmet medical need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investigational-agent-profile\">Investigational Agent Profile<\/h2>\n\n\n\n<p><strong>SHR-A2009<\/strong> represents Hengrui&#8217;s proprietary ADC platform advancement:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: <strong>HER3 (ERBB3)<\/strong>, a member of the EGFR family frequently expressed in EGFR-mutated NSCLC<\/li>\n\n\n\n<li><strong>Structure<\/strong>: <strong>Fully human HER3 monoclonal antibody<\/strong> conjugated to a <strong>DNA topoisomerase I inhibitor<\/strong> payload<\/li>\n\n\n\n<li><strong>Development Status<\/strong>: <strong>In-house developed<\/strong> by Hengrui, demonstrating internal ADC platform capabilities<\/li>\n\n\n\n<li><strong>Mechanism Rationale<\/strong>: HER3 expression often persists or increases after EGFR TKI resistance develops, providing a rational target for ADC therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-unmet-need\">Market Opportunity &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Approximately <strong>30,000-40,000 patients annually<\/strong> in major markets develop resistance to EGFR TKIs<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Limited options post-TKI failure, with platinum chemotherapy providing modest benefit and significant toxicity<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: No approved HER3-targeting therapies in NSCLC, positioning SHR-A2009 as potential first-in-class<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Analysts project peak annual sales of <strong>$800 million to $1.2 billion<\/strong> if approved globally<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-pathway-amp-next-steps\">Regulatory Pathway &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Action<\/strong>: Hengrui plans to submit a <strong>pre-NDA communication request<\/strong> to China&#8217;s <strong>Center for Drug Evaluation (CDE)<\/strong> of the <strong>National Medical Products Administration (NMPA)<\/strong><\/li>\n\n\n\n<li><strong>Timeline Expectations<\/strong>: Potential NDA submission in <strong>Q4 2026<\/strong> with accelerated review pathway likely<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: Success supports parallel regulatory filings with <strong>FDA and EMA<\/strong> for international markets<\/li>\n\n\n\n<li><strong>Label Differentiation<\/strong>: First ADC to demonstrate PFS benefit in post-TKI EGFR-mutated NSCLC provides strong competitive positioning<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-hengrui\">Strategic Implications for Hengrui<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Platform Validation<\/strong>: Success demonstrates Hengrui&#8217;s capability to develop best-in-class ADCs internally<\/li>\n\n\n\n<li><strong>Oncology Portfolio Expansion<\/strong>: Complements existing immuno-oncology and targeted therapy portfolio<\/li>\n\n\n\n<li><strong>International Recognition<\/strong>: Phase III success in competitive NSCLC space enhances global credibility<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Potential blockbuster asset reduces reliance on existing commercial products<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER3 Target Race<\/strong>: Multiple companies developing HER3-targeting agents, but Hengrui appears to be first to demonstrate Phase III success in NSCLC<\/li>\n\n\n\n<li><strong>ADC Market Leadership<\/strong>: Positions Hengrui among elite Chinese biopharma companies with validated ADC platforms<\/li>\n\n\n\n<li><strong>TKI Resistance Focus<\/strong>: Addresses critical gap in EGFR-mutated NSCLC treatment paradigm<\/li>\n\n\n\n<li><strong>Combination Potential<\/strong>: Future studies may explore SHR-A2009 in combination with next-generation TKIs or immunotherapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile-considerations\">Safety Profile Considerations<\/h2>\n\n\n\n<p>While detailed safety data was not disclosed in the announcement, the comparison to platinum-based chemotherapy suggests:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toxicity Advantage<\/strong>: ADC approach may offer improved tolerability compared to traditional chemotherapy<\/li>\n\n\n\n<li><strong>Outpatient Administration<\/strong>: Potential for less intensive supportive care requirements<\/li>\n\n\n\n<li><strong>Quality of Life<\/strong>: Reduced toxicity burden could translate to better patient-reported outcomes<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for SHR-A2009. Actual results may differ due to risks including final trial data analysis, regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65683,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,17,2586,4228,852],"class_list":["post-65682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-results","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301 trial for its investigational HER3-targeting antibody drug conjugate (ADC) SHR-A2009 met its primary endpoint with statistical significance in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations who have failed prior EGFR tyrosine kinase inhibitor (TKI) therapy. The study demonstrated that SHR-A2009 significantly prolonged progression-free survival (PFS) compared to platinum-based doublet chemotherapy, establishing a potential new standard of care in this difficult-to-treat population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65682\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301 trial for its investigational HER3-targeting antibody drug conjugate (ADC) SHR-A2009 met its primary endpoint with statistical significance in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations who have failed prior EGFR tyrosine kinase inhibitor (TKI) therapy. The study demonstrated that SHR-A2009 significantly prolonged progression-free survival (PFS) compared to platinum-based doublet chemotherapy, establishing a potential new standard of care in this difficult-to-treat population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65682\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T13:57:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T13:57:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure\",\"datePublished\":\"2026-05-19T13:57:09+00:00\",\"dateModified\":\"2026-05-19T13:57:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682\"},\"wordCount\":559,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1905.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial results\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65682#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65682\",\"name\":\"Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1905.webp\",\"datePublished\":\"2026-05-19T13:57:09+00:00\",\"dateModified\":\"2026-05-19T13:57:10+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301 trial for its investigational HER3-targeting antibody drug conjugate (ADC) SHR-A2009 met its primary endpoint with statistical significance in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations who have failed prior EGFR tyrosine kinase inhibitor (TKI) therapy. The study demonstrated that SHR-A2009 significantly prolonged progression-free survival (PFS) compared to platinum-based doublet chemotherapy, establishing a potential new standard of care in this difficult-to-treat population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65682\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1905.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65682#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301 trial for its investigational HER3-targeting antibody drug conjugate (ADC) SHR-A2009 met its primary endpoint with statistical significance in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations who have failed prior EGFR tyrosine kinase inhibitor (TKI) therapy. The study demonstrated that SHR-A2009 significantly prolonged progression-free survival (PFS) compared to platinum-based doublet chemotherapy, establishing a potential new standard of care in this difficult-to-treat population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65682","og_locale":"en_US","og_type":"article","og_title":"Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301 trial for its investigational HER3-targeting antibody drug conjugate (ADC) SHR-A2009 met its primary endpoint with statistical significance in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations who have failed prior EGFR tyrosine kinase inhibitor (TKI) therapy. The study demonstrated that SHR-A2009 significantly prolonged progression-free survival (PFS) compared to platinum-based doublet chemotherapy, establishing a potential new standard of care in this difficult-to-treat population.","og_url":"https:\/\/flcube.com\/?p=65682","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T13:57:09+00:00","article_modified_time":"2026-05-19T13:57:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65682#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65682"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure","datePublished":"2026-05-19T13:57:09+00:00","dateModified":"2026-05-19T13:57:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65682"},"wordCount":559,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65682#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp","keywords":["ADC \/ XDC","Clinical trial results","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65682#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65682","url":"https:\/\/flcube.com\/?p=65682","name":"Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65682#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65682#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp","datePublished":"2026-05-19T13:57:09+00:00","dateModified":"2026-05-19T13:57:10+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the Phase III SHR-A2009-301 trial for its investigational HER3-targeting antibody drug conjugate (ADC) SHR-A2009 met its primary endpoint with statistical significance in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations who have failed prior EGFR tyrosine kinase inhibitor (TKI) therapy. The study demonstrated that SHR-A2009 significantly prolonged progression-free survival (PFS) compared to platinum-based doublet chemotherapy, establishing a potential new standard of care in this difficult-to-treat population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65682#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65682"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65682#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp","width":1080,"height":608,"caption":"Hengrui's HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65682#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65682"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65682\/revisions"}],"predecessor-version":[{"id":65684,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65682\/revisions\/65684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65683"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}